HC Wainwright restated their buy rating on shares of Indaptus Therapeutics (NASDAQ:INDP – Free Report) in a research note released on Monday morning, Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q1 2024 earnings at ($0.57) EPS, Q2 2024 earnings at ($0.60) […]